Skip to main content
. 2024 Feb 2;39(Suppl 1):i33–i49. doi: 10.1093/heapol/czad099

Table 3.

Coverage indicators and domestic and GFATM financing mix for the Anti-Malaria Campaign (AMC)

Malaria casesa Expenditure for AMC (USD million (% of total))f
Year GFATM funding timelines Indigenous Imported Introduced Entomological surveillance daysd Number of blood films screened from risk populationse Domesticg World Bank GFATM UN agencies Total
2003 GFATM funding initiation 10510h N/A 1 192 259 1.73 (40.8) 0.11 (2.6) 2.40 (56.6) 0.00 (0.0) 4.24 (100.0)
2004 3720 h N/A 1 198 181 2.62 (60.5) 0.00 (0.0) 1.71 (39.5) 0.00 (0.0) 4.33 (100.0)
2005 1640 h N/A 973 861 1.02 (61.1) 0.00 (0.0) 0.65 (38.9) 0.00 (0.0) 1.67 (100.0)
2006 591 h N/A 1 076 121 2.38 (95.2) 0.00 (0.0) 0.12 (4.8) 0.00 (0.0) 2.50 (100.0)
2007 199 h N/A 1 044 403 1.40 (65.4) 0.00 (0.0) 0.74 (34.6) 0.00 (0.0) 2.14 (100.0)
2008 646 24 N/A 1 047 104 2.74 (41.1) 0.00 (0.0) 3.93 (58.9) 0.00 (0.0) 6.67 (100.0)
2009 531 27 N/A 909 632 1.42 (17.7) 0.00 (0.0) 6.59 (82.3) 0.00 (0.0) 8.01 (100.0)
2010 684 52 1898 1 098 779 1.17 (17.4) 0.00 (0.0) 5.57 (82.6) 0.00 (0.0) 6.74 (100.0)
2011 124 51 7067 1 243 040 1.23 (21.7) 0.00 (0.0) 4.38 (77.2) 0.06 (1.1) 5.67 (100.0)
2012 23 70 7052 1 186 165 0.56 (17.2) 0.00 (0.0) 2.62 (80.4) 0.08 (2.4) 3.26 (100.0)
2013 0 95 0 8129 1 236 579 0.60 (13.2) 0.00 (0.0) 3.88 (85.5) 0.06 (1.3) 4.54 (100.0)
2014 0 49 0 N/A 1 232 314 0.74 (23.8) 0.00 (0.0) 2.32 (74.6) 0.05 (1.6) 3.11 (100.0)
2015 0 36 0 4248 1 142 466 0.91 (58.0) 0.00 (0.0) 0.63 (40.1) 0.03 (1.9) 1.57 (100.0)
2016 Transition 0 41 0 4901 1 072 396 1.09 (55.1) 0.00 (0.0) 0.85 (42.9) 0.04 (2.0) 1.98 (100.0)
2017 0 56 0 4321 1 089 290 0.89 (36.8) 0.00 (0.0) 1.52 (62.8) 0.01 (0.4) 2.42 (100.0)
2018 0 47 1b 4628 1 129 070 0.97 (23.9) 0.00 (0.0) 3.08 (75.9) 0.01 (0.2) 4.06 (100.0)
2019 GFATM post-transition commences 0 53 0 4830 1 164 914 1.05 (99.1) 0.00 (0.0) 0.00 (0.0) 0.01 (0.9) 1.06 (100.0)
2020 0 30 0 3830 820 210 N/A N/A N/A N/A N/A
2021 0 22 1c 4662 673 744 N/A N/A N/A N/A N/A
2022 0 30i 0 N/A N/A N/A N/A N/A N/A N/A
a

Data for 2003–2005: (Abeyasinghe et al., 2012); 2006–2019: AMC Annual Reports (http://www.malariacampaign.gov.lk/en/resources/annual-reports, [accessed 10 February 2023]) and 2020–2021: Anti-Malaria Campaign, Ministry of Health Sri Lanka unpublished data; 2022 AMC website https://web.archive.org/web/20221126024221/http://amc.health.gov.lk/en/, [accessed 10 February 2023].

b

Introduced malaria case reported in 2018 (Karunasena et al., 2019).

c

Blood transfusion-induced malaria case reported in 2021 (Chulasiri et al., 2021).

d

Data for 2010–2019: AMC Annual Reports (http://www.malariacampaign.gov.lk/en/resources/annual-reports, [accessed 12 February 2023]) and 2020–2021: Anti-Malaria Campaign, Ministry of Health Sri Lanka unpublished data.

e

Data for 2003–2005: (Premaratne et al., 2019); 2006–2016, 2018–2019 AMC Annual Reports (http://www.malariacampaign.gov.lk/en/resources/annual-reports, [accessed 25 January 2023], 2007: (Gunasekera et al., 2021); and 2020–2021: Anti-Malaria Campaign, Ministry of Health Sri Lanka unpublished data.

f

Expenditure data from Institute for Health Policy (IHP) Sri Lanka Health Accounts Database. Expenditure for 2019 is provisional.

g

Domestic financing includes AMC directorate expenditure and medical supplies and other expenditures (e.g, equipment) supplied by the AMC directorate to the provinces. This excludes recurrent expenditure (salaries and other overheads) at the provincial level.

h

Disaggregation of cases as indigenous and imported are not available. AMC began classifying cases from 2008 onwards.

i

Total cases up to November.

N/A indicates not available.